Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant

Transthyretin amyloidosis (ATTR) variant is a life-threatening hereditary disease predominantly affecting the peripheral nervous system and heart. Tafamidis, which prevents the deposition of amyloid by stabilizing transthyretin, is available for the treatment of neuropathy and cardiomyopathy of ATTR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of Medical Investigation 2022, Vol.69(3.4), pp.320-322
Hauptverfasser: Yagi, Shusuke, Yamazaki, Hiromu, Kusunose, Kenya, Osaki, Yusuke, Ise, Takayuki, Kadota, Muneyuki, Tserensonom, Munkhtsetseg, Kawabata, Yutaka, Hara, Tomoya, Ueno, Rie, Saijo, Yoshihito, Matsuura, Tomomi, Yamaguchi, Koji, Yamada, Hirotsugu, Fukuda, Daiju, Soeki, Takeshi, Wakatsuki, Tetsuzo, Sata, Masataka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Transthyretin amyloidosis (ATTR) variant is a life-threatening hereditary disease predominantly affecting the peripheral nervous system and heart. Tafamidis, which prevents the deposition of amyloid by stabilizing transthyretin, is available for the treatment of neuropathy and cardiomyopathy of ATTR. However, whether tafamidis could eliminate established amyloid deposits and improve cardiac function remains unknown. We reported a case of regression of left ventricular hypertrophy after tafamidis therapy in a patient with an ATTR variant. J. Med. Invest. 69 : 320-322, August, 2022
ISSN:1343-1420
1349-6867
DOI:10.2152/jmi.69.320